Regulator steps up oversight of GLP-1 drug distribution chain

Regulatory actions are a key driver for the Indian pharma sector, influencing operational costs and market access. Increased oversight on GLP-1 drugs reflects growing concerns over their misuse and improper practices.

• •India's drug regulatory body is intensifying scrutiny of GLP-1 weight loss drug distribution channels.
• •State drug authorities are directed to ensure stringent compliance with approved protocols and accurate product labeling.
• •Unauthorized sale or marketing will lead to strict legal action.
• •The agency is also closely watching promotional activities across different platforms.
• •Risk flag: Increased compliance costs for manufacturers and distributors.